AIM ImmunoTech Inc. Stock News

Live video webcast on Wednesday, January 18th at 11:00 AM ET Live video webcast on Wednesday, January 18th at 11:00 AM ET

AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scientific officer. The immuno-pharma firm said McAlee

AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal administration of its lead product Ampligen (rintat

AIM ImmunoTech Inc (NYSE:AIM) said it ended the third quarter of 2022 with cash and cash equivalents of $36.7 million, down from $48.3 million at the end of December 2021, but expected to fund operat

AIM ImmunoTech Inc (NYSE:AIM) has revealed positive data evaluating Ampligen (rintatolimod) as a component of a regimen for the treatment of early-stage triple negative breast cancer. Led by by Roswe

Aimia is trading approximately around its net cash plus marketable securities value. Applying punitive discounts to its private investments, Aimia's NAVPS is roughly 30% above where the stock is tradi

Aimia, Inc. (OTCPK:AIMFF) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Albert Matousek - Head, IR & Communications Phil Mittleman - CEO Michael Lehmann - President

AIM ImmunoTech Inc (NYSE:AIM) said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience. AIM ImmunoTech also said its board compensation

AIM ImmunoTech Inc (NYSE:AIM) announced that its dsRNA product candidate Ampligen (rintatolimod) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatmen

AIM ImmunoTech Inc (NYSE:AIM) said the Delaware Court of Chancery has denied an activist investor's bid to put two nominees on its board during the November 3 annual meeting of shareholders. In its d

AIM ImmunoTech Inc (NYSE:AIM) told investors it expects to begin enrolling patients in the first quarter next year for a Phase 2 trial of its investigational drug Ampligen as a therapeutic for patient

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra I

OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut

AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen (rintatolimo